Elicio Therapeutics Presents Preclinical Data on its Amphiphile-CpG Adjuvant at the STING & TLR-Targeting Therapies Summit 2022 Digital Event – QNT Press Release

[ad_1]

  • AMP-CpG targets efficiently the lymph nodes to promote potent and comprehensive innate immune activation resulting in enhanced T and B cell responses with improved functionality and persistence
  • Application of AMP-CpG enables potent anti-tumor responses in multiple settings of therapy including therapeutic vaccination and TCR-T cell therapy
  • Application of AMP-CpG enables potent and balanced immunity, including CD8 and CD4 T cells as well as neutralizing cross-reactive antibodies, against viral pathogens

BOSTON, March 23, 2022 (GLOBE NEWSWIRE) — Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the presentation of preclinical data demonstrating that its lymph node-targeted CpG TLR9 agonist, Amphiphile-CpG (AMP-CpG), induces potent immune and anti-tumor responses, at the STING & TLR-Targeting Therapies Summit 2022 Digital Event, being held virtually from March 22-24, 2022. The electronic presentation is accessible here.

“We are excited to see the preclinical responses observed across studies with our AMP platform. These responses reinforce previous findings and continue to demonstrate how targeted delivery of AMP-CpG to the lymph nodes promotes a potent cellular immune response to the respective disease-associated antigens – validating our lymph node-targeted approach to treating cancer and infectious diseases,” said Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics. “These preclinical datasets have also informed our AMP boosting approach to enhance established T cell receptor therapies (TCR-Ts).”

The AMP platform is designed to deliver therapeutic payloads directly to the lymph nodes, the “schoolhouse” of the immune system, activating a potent, functional and durable immune response. Elicio’s AMP platform with the CpG adjuvant has been shown to enhance the accumulation of AMP -CpG bound payloads in the lymph nodes, thus educating the body’s immune cells and resulting in a more potent immune response. This has enabled Elicio to unlock the untapped potential of lymph node-targeting for the treatment of several indications. In SARS-CoV- 2, for example, vaccination with AMP-CpG demonstrated potent and durable T cell responses across several variants of concern. When combined with TCR-Ts, AMP-CpG enhances TCR-T cell persistence and anti-tumor function. Elicio has also demonstrated potent responses with its AMP-CpG adjuvant across a range of other antigens including those from Epstein-Barr virus, human papillomavirus and influenza.

Presentation Details

Title: Lymph-Node Targeted TLR9 Agonists Enable Potent Cellular Immune Responses Against Cancer & Infectious Disease

Highlights from the Presentation

  • AMP-CpG…

Full story available on Benzinga.com

[ad_2]

Source link

Recommended For You

About the Author: News Center